EMBO Reports<\/em><\/strong><\/a> indica que este efecto antitumoral vendr\u00eda dado, en parte, por su papel en la regulaci\u00f3n de la v\u00eda Wnt\/\u03b2-catenina.<\/p>\n\u00abEntender por qu\u00e9 se generan tumores, los mecanismos moleculares subyacentes y el papel que juega cada uno nos da una perspectiva m\u00e1s amplia<\/em> -afirma Ruth Rodr\u00edguez-Barrueco<\/strong>, investigadora principal del IDIBELL y la Universidad de Barcelona.- Una perspectiva que nos permite seguir explorando nuevas dianas terap\u00e9uticas, que podamos modular, para obtener tratamientos m\u00e1s eficaces y con menos efectos secundarios para las pacientes<\/em>\u00ab.<\/p>\nLos microRNAs son peque\u00f1os fragmentos de \u00e1cidos nucleicos que regulan de manera espec\u00edfica la expresi\u00f3n de ciertos genes. \u00abNosotros hemos observado que los microRNA miR-424 y miR-503 bloquean la s\u00edntesis de un receptor esencial para la v\u00eda de se\u00f1alizaci\u00f3n Wnt\/\u03b2-catenina. Se trata de una estrategia de las c\u00e9lulas del epitelio mamario para regular la proliferaci\u00f3n celular<\/em>\u00bb afirma el Dr. David Llobet-Nav\u00e0s<\/strong>, tambi\u00e9n investigador principal del IDIBELL y la Universidad de Barcelona y miembro del CIBERONC. \u00abCon este estudio nosotros proponemos que cuando desaparece este grupo de microRNAs desaparece el freno de la proliferaci\u00f3n celular en el epitelio mamario, y por tanto, se puede favorecer el crecimiento descontrolado y la aparici\u00f3n eventual de tumores<\/em>\u00ab.<\/p>\nPara esta investigaci\u00f3n, el equipo ha utilizado un modelo de rat\u00f3n que no expresa el grupo de microRNAs miR-424~<\/sup>503<\/strong>. Los investigadores han observado que las hembras que no expresan estos microRNAs desarrollan m\u00e1s frecuentemente tumores en la gl\u00e1ndula mamaria que se caracterizan por una sobreactivaci\u00f3n de la v\u00eda Wnt\/\u03b2-catenina.<\/p>\n <\/p>\n
<\/p>\n
El Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) es un centro de investigaci\u00f3n en biomedicina creado en 2004. Est\u00e1 participado por el Hospital Universitario de Bellvitge y el Hospital de Viladecans del Instituto Catal\u00e1n de la Salud, el Instituto Catal\u00e1n de Oncolog\u00eda, la Universidad de Barcelona y el Ayuntamiento de L’Hospitalet de Llobregat.<\/em><\/p>\nEl IDIBELL es miembro del Campus de Excelencia Internacional de la Universidad de Barcelona HUBc y forma parte de la instituci\u00f3n CERCA de la Generalitat de Catalunya. En 2009 se convirti\u00f3 en uno de los cinco primeros centros de investigaci\u00f3n espa\u00f1oles acreditados como instituto de investigaci\u00f3n sanitaria por el Instituto de Salud Carlos III. Adem\u00e1s, forma parte del programa \u00abHR Excellence in Research\u00bb de la Uni\u00f3n Europea y es miembro de EATRIS y REGIC. Desde el a\u00f1o 2018, IDIBELL es un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Investigadores del IDIBELL y la UB, conjuntamente con el Mount Sinai, han descrito un conjunto de microRNAs que estar\u00edan regulando los c\u00e1nceres de mama dependientes de la v\u00eda de se\u00f1alizaci\u00f3n Wnt\/\u03b2-catenina.<\/p>\n","protected":false},"author":8,"featured_media":18662,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,253,281],"tags":[],"class_list":["post-18661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-cancer-ginecologico","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-12-01 04:39:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/18661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=18661"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/18661\/revisions"}],"predecessor-version":[{"id":18663,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/18661\/revisions\/18663"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/18662"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=18661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=18661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=18661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}